Since its inception, Atomwise has made significant strides in the biotechnology industry, raising a total of $176.42 million in funding. This substantial ...

25 янв. 2022 г. · Atomwise strengthens its management team, adds veteran biopharma leader David Thomson, Ph.D. as Chief Scientific Officer and two additional senior appointments.

Atomwise is a privately held company and is not publicly traded, therefore investing in Atomwise pre-IPO is only available to accredited investors. If you meet ...

Accredited investors can buy pre-IPO stock in companies like Atomwise through EquityZen funds. These investments are made available by existing Atomwise ...

17 июн. 2021 г. · Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB).

Atomwise raises $123 million to accelerate drug discovery with AI. Atomwise, a company leveraging AI and machine learning to accelerate drug discovery, has ...

12 сент. 2019 г. · The IPO generated HK$7.86 billion (approximately $1 billion) in net proceeds, topping GEN's A-List of the Top 10 Biopharma IPOs of January-June ...

11 авг. 2020 г. · Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil. New financing will enable Atomwise to further scale ...

11 авг. 2020 г. · Atomwise, which is using artificial intelligence for small molecule drug discovery, received a cash infusion of $123 million in an oversubscribed Series B ...

2 окт. 2023 г. · Atomwise, one of the first startups to start pitching an AI revolution in drug discovery just over a decade ago is now taking a page.